According to The Insight Partners' research, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market was valued at US$ 875.4 Million in 2024 and is expected to reach US$ 1,655.0 Million by 2031, registering a CAGR of 9.3% from 2025 to 2031.
Rising demand for biologics and increasing demand for cost efficiency and flexibility are among the critical factors attributed to driving the Middle East & Africa biopharmaceutical contract manufacturing market growth.
Biologics are the basis of modern medicine due to their increased efficacy in treating complex and chronic diseases such as cancer, autoimmune disorders, and genetic conditions. Monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins are some of the major biologics used prominently in medical services. As per the National Cancer Institute, ~20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022. The rising number of such chronic conditions creates the demand for biologics, leading to the increased collaboration of pharmaceutical manufacturers with contract manufacturing organizations (CMOs) specializing in biologics manufacturing capabilities. Biology manufacturing is a complex process and requires highly specialized equipment, expertise, and facilities. The long production timelines and high costs associated with setting up in-house manufacturing facilities for biology make outsourcing more crucial. CMOs provide the necessary infrastructure and expertise to scale production, allowing drug developers to meet market demand without any significant capital investment. Manufacturers such as Roche and Bristol-Myers Squibb have developed monoclonal antibody-based biologics, Herceptin and Opdivo, with the help of CMOs, which have transformed cancer treatments. These therapies have significantly increased the demand for contract manufacturing services as companies look for specialized facilities capable of producing these highly complex biologics on a large scale. Therefore, the rising demand for biologics has created the need for specialized, cost-effective, and scalable production solutions, which fuels the growth of the biopharmaceutical contract manufacturing market.
On the contrary, the tightened budget and economic uncertainty hamper the growth of the Middle East & Africa biopharmaceutical contract manufacturing market.
Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation Analysis:
- By Product Type, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market is segmented into Biologics and Biosimilar. The Biologics segment is projected to expand at 9.4% CAGR during 2025 - 2031.
- By Source, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market is segmented into Microbial and Mammalian. The Microbial segment is projected to expand at 9.6% CAGR during 2025 - 2031.
- By Application, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market is segmented into Commercial and Clinical. The Commercial segment is projected to expand at 9.8% CAGR during 2025 - 2031.
- By Therapeutic Area, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market is segmented into Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others. The Oncology segment is projected to expand at 10.0% CAGR during 2025 - 2031.
By country, the Middle East & Africa Biopharmaceutical Contract Manufacturing Market is categorized into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa is projected to expand at 9.6% CAGR during 2025 - 2031.
Key players operating in the Biopharmaceutical Contract Manufacturing Market are Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co., Ltd., WuXi Biologics Inc, Merck KGaA, Ajinomoto Co., Inc, Cytiva, and AGC Biologics AS, among others.
- In 2025, with the growth and transformation of the mAb market, particularly with the recent rapid rise of biosimilars, a one-size-fits-all approach to protein purification is no longer viable. To address this, Cytiva developed two new protein A resins: the MabSelect SuRe 70 and the MabSelect PrismA X.
- In 2025, WuXi Biologics Launched EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production. EffiX is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe. EffiX delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com